An interventional study of Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol and Placebo in Uterine Fibroids, D-chiro-inositol and Inositol, sponsored by Lo.Li.Pharma s.r.l. Recruiting at 2 sites in Italy. Open to female participants aged 30 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Lo.Li.Pharma s.r.l · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Leiomyoma with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Leiomyoma · Italy.
Among the 30 studies in Leiomyoma with a site in Italy, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 with no phase, and was the 24th registered.
439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →5 of the 30 studies in Leiomyoma with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Women only
Emanuele Barabino · Sites in Italy
Ages 18–55 · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–80 · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 30 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 66 across 307 interventional studies indexed under Leiomyoma.
Median enrollment 133 across the 18 interventional studies, 131 across the 12 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 30 have an industry lead sponsor. The 10 most frequent:
Lo.Li.Pharma s.r.l is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Lo.Li.Pharma s.r.l has 1 study filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Leiomyoma with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07230444Emanuele BarabinoArtificial Intelligence for the Intra-procedural Assessment of Uterine Artery Embolization | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Leiomyoma with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6.
The patients will be evaluated at baseline and after three months of treatment with placebo or product.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women with uterine fibroids randomized to treatment group
Dietary Supplement: Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol
Women with uterine fibroids randomized to placebo group
Dietary Supplement: Placebo
Drug pages: Epigallocatechin gallateStudies of Epigallocatechin gallateEpigallocatechin gallate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Vitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Vitamin B 6Studies of Vitamin B 6Vitamin B 6 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PyridoxineStudies of PyridoxinePyridoxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Chiro-inositol, (+)-Studies of Chiro-inositol, (+)-Chiro-inositol, (+)- pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
Maltodextrines
Diameter
Greater diameter of the diagnosed uterine fibroids
Time frame: 3 months
Volume
Total volume of the diagnosed uterine fibroids
Time frame: 3 months
Need for surgery
The percentage of patients that decide to avoid surgery
Time frame: 3 months
pVEGF-R
the phosphorilation of VEGF receptor
Time frame: 3 months
Marker of cellular proliferation
expression of ki67, ER, PR
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Mar 2026, 44 months after the start.
Of 58 interventional studies with no phase under Leiomyoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 44 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Epigallocatechin gallate · Vitamin D · Vitamin B 6 · Pyridoxine · Chiro-inositol, (+)-